摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

perfluoro-N-methyl-decahydroquinoline | 86714-33-2

中文名称
——
中文别名
——
英文名称
perfluoro-N-methyl-decahydroquinoline
英文别名
2,2,3,3,4,4,4a,5,5,6,6,7,7,8,8,8a-hexadecafluoro-1-(trifluoromethyl)quinoline
perfluoro-N-methyl-decahydroquinoline化学式
CAS
86714-33-2
化学式
C10F19N
mdl
——
分子量
495.086
InChiKey
SCPDYEAXXZZBIC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    134.1±40.0 °C(Predicted)
  • 密度:
    1.88±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    6.4
  • 重原子数:
    30
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    3.2
  • 氢给体数:
    0
  • 氢受体数:
    20

SDS

SDS:f41692735830be25fe1607abd9d4c7e9
查看

反应信息

  • 作为反应物:
    描述:
    perfluoro-N-methyl-decahydroquinoline五氟化锑 作用下, 反应 0.5h, 以84%的产率得到pentadecafluoro-2-azabicyclo<4,4,0>dec-1-(2)ene
    参考文献:
    名称:
    Splitting of perfluorinated tertiary cyclic amines by the action of SbF5
    摘要:
    It was shown that perfluorinated tertiary cyclic amines are dealkylated by the action of SbF5 with the formation of cyclic azomethines. The presence of a perfluoroalkyl substitutent in the alpha-position to the nitrogen atom in the amine molecule considerably decreases its stability to the action of antimony pentafluoride.
    DOI:
    10.1007/bf00957861
  • 作为产物:
    参考文献:
    名称:
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • [EN] PHOTOSENSITIZER PARTICLES FOR MEDICAL IMAGING AND/OR PHOTODYNAMIC THERAPY<br/>[FR] PARTICULES DE PHOTOSENSIBILISATEUR DESTINÉES À L'IMAGERIE MÉDICALE ET/OU À LA THÉRAPIE PHOTODYNAMIQUE
    申请人:DCB USA LLC
    公开号:WO2014189796A1
    公开(公告)日:2014-11-27
    Photosensitizer particle contrast agents are suitable for medical imaging and/or photodynamic therapy. The photosensitizer particle contrast agent has a shell and a core encased by the shell. The shell consists essentially of multiple photosensitizer conjugates. Each photosensitizer conjugate consists of a photosensitizer and at least one biodegradable polymer covalently bound to the photosensitizer. The core has an echogenic contrast-enhancing material loaded therein. The photosensitizer of at least one of the multiple photosensitizer conjugates has a magnetic contrast-enhancing agent, e.g., a paramagnetic ion, chelated thereto. Methods for medical imaging use imaging compositions containing the photosensitizer particle contrast agents.
    光敏剂颗粒对比剂适用于医学成像和/或光动力疗法。光敏剂颗粒对比剂具有一个被壳包裹的壳和核心。壳主要由多个光敏剂结合物组成。每个光敏剂结合物由光敏剂和至少一个与光敏剂共价结合的可生物降解聚合物组成。核心中装载有增强超声对比的材料。多个光敏剂结合物中至少一个的光敏剂具有磁性增强对比剂,例如,螯合到其中的顺磁离子。用于医学成像的方法使用含有光敏剂颗粒对比剂的成像组合物。
  • PHOTOSENSITIZER PARTICLES FOR MEDICAL IMAGING AND/OR PHOTODYNAMIC THERAPY
    申请人:DCB-USA LLC
    公开号:US20160082127A1
    公开(公告)日:2016-03-24
    Disclosed herein are photosensitizer particle contrast agents suitable for medical imaging and/or photodynamic therapy. The photosensitizer particle contrast agent has a shell and a core encased by the shell. The shell consists essentially of multiple photosensitizer conjugates. Each photosensitizer conjugate consists of a photosensitizer and at least one biodegradable polymer covalently bound to the photosensitizer. According to certain examples, the core has an echogenic contrast-enhancing material loaded therein. In alternative examples, the photosensitizer of at least one of the multiple photosensitizer conjugates has a magnetic contrast-enhancing agent, e.g., a paramagnetic ion, chelated thereto. Also disclosed herein are methods for medical imaging which use imaging compositions containing the photosensitizer particle contrast agents taught in the present disclosure.
    本文揭示了适用于医学成像和/或光动力疗法的光敏剂颗粒对比剂。该光敏剂颗粒对比剂具有一个由壳和核组成的外壳。壳主要由多种光敏剂结合物组成。每个光敏剂结合物由光敏剂和至少一种生物可降解聚合物共价结合于光敏剂上组成。根据某些示例,核内装有超声对比增强材料。在另一些示例中,至少一种多种光敏剂结合物的光敏剂具有磁性对比增强剂,例如配位到其中的顺磁离子。本文还揭示了使用本文所教授的光敏剂颗粒对比剂制备的成像组成物进行医学成像的方法。
  • Stable emulsions of highly fluorinated organic compound
    申请人:CHILDREN'S HOSPITAL MEDICAL CENTER
    公开号:EP0231091A1
    公开(公告)日:1987-08-05
    Stable emulsions of highly fluorinated organic compounds for use as oxygen transport agents, "artificial bloods" or red blood cell substitutes and as contrast agents for biological imaging. The emulsions comprise a highly fluorinated organic compound, an oil that is not substantially surface active and not significantly soluble in water, a surfactant and water.
    高氟有机化合物的稳定乳剂,可用作氧运输剂、"人造血液 "或红细胞替代物以及生物成像的造影剂。乳剂由高氟有机化合物、表面活性不强且不太溶于水的油类、表面活性剂和水组成。
  • Internal organ-preserving liquid and method for preserving internal organs
    申请人:THE GREEN CROSS CORPORATION
    公开号:EP0440925A1
    公开(公告)日:1991-08-14
    Organ-preserving liquids comprising, as an active ingredient, an undiluted liquid of a perfluorocarbon compound or an emulsion containing the same at a high concentration and methods for preserving internal organs are disclosed. The internal organ-preserving liquids of the present invention are extremely useful in the clinical situations as organ-preserving liquids in organ transplantation for mammals including humans, especially as preserving liquids for internal organs having likelihood of thermal ischemic disorders. According to the present invention, internal organs (e.g. pancreas, liver) are preserved by immersing the internal organs in an undiluted liquid of a perfluorocarbon or an emulsion thereof at a high concentration, preferably, with oxygen bubbling.
    本发明公开了由未稀释的全氟碳化合物液体或含有高浓度全氟碳化合物的乳液作为活性成分的器官保存液以及保存内脏器官的方法。本发明的内脏器官保存液作为哺乳动物(包括人类)器官移植中的器官保存液在临床上非常有用,特别是作为有可能发生热缺血性疾病的内脏器官的保存液。 根据本发明,将内脏器官(如胰腺、肝脏)浸泡在未稀释的高浓度全氟碳化合物或其乳液中,最好伴有氧气气泡,从而保存内脏器官。
  • Scavenging dissolved oxygen via acoustic droplet vaporization
    申请人:UNIVERSITY OF CINCINNATI
    公开号:US10688039B2
    公开(公告)日:2020-06-23
    Methods and compositions for treating a patient for a condition characterized by an excess blood concentration of dissolved gas in at least one targeted region of the patient are provided. The method comprises administering a composition comprising a perfluorocarbon droplet emulsion into the blood of the patient; insonifying the at least one target region sufficient to achieve formation of microbubbles by droplet vaporization of at least a portion of the perfluorocarbon droplets present in the blood; whereby a concentration gradient favoring movement of gas molecules from the blood into the microbubbles is established for a time frame.
    本发明提供了用于治疗以患者至少一个目标区域血液中溶解气体浓度过高为特征的疾病的方法和组合物。该方法包括向患者血液中施用包含全氟碳液滴乳液的组合物;对至少一个目标区域进行足够的电离,以通过血液中存在的至少一部分全氟碳液滴的液滴汽化形成微气泡;从而在一段时间内建立有利于气体分子从血液进入微气泡的浓度梯度。
查看更多

同类化合物

锯齿石松宁 箭毒蛙毒素 C 坎库碘铵 十氢喹啉 十氢-2-甲基喹啉 八氢对苯二酚-4(1H)-酮 八氢喹啉-2(1H)-酮 八氢-2,6-喹啉二酮 [(4aS,4bR,6aS,8S,10aS,10bS,12aS)-10a,12a-二甲基-1,2,3,4,4a,4b,5,6,6a,7,8,9,10,10b,11,12-十六氢萘并[6,5-f]喹啉-8-基]2-[4-[二(2-氯乙基)氨基]苯基]乙酸酯 [(4aS,4bR,6aS,8S,10aS,10bS,12aS)-1,10a,12a-三甲基-2-氧代-3,4,4a,4b,5,6,6a,7,8,9,10,10b,11,12-十四氢萘并[6,5-f]喹啉-8-基]2-[4-[二(2-氯乙基)氨基]苯基]乙酸酯 8H-13,3,6a-乙基亚基-7,10-亚甲基噁庚并[3,4-i]-1-苯并吖辛因-8-酮,1-乙基十四氢-12a-羟基-6-甲氧基-3-甲基-,(3R,6S,6aS,7R,7aS,10S,12aS,13S,13aR,15R)-(9CI) 8-羟基-十氢喹啉 4-乙炔基-2-甲基十氢喹啉-4-醇 3-羟基-13,17-开环-5-雄甾烯-17-酸-13,17-内酰胺(4-(二(2-氯乙基)氨基)苯基)丁酸酯 2,5-二丙基十氢喹啉 1-(3-氯-丙基)-十氢-喹啉 1,2,2-三甲基-八氢-喹啉-4-酮 (4aS,4bR,8S,10aR,10bS,12aS)-10a,12a-二甲基-2-羰基-1,2,3,4,4a,4b,5,7,8,9,10,10a,10b,11,12,12a-十六氢萘并[2,1-f]喹啉-8-基{4-[二(2-氯乙基)氨基]苯基}乙酸酯 (4aS,4bR,6aS,8S,10aS,10bS,12aS)-8-羟基-10a,12a-二甲基-3,4,4a,4b,5,6,6a,7,8,9,10,10b,11,12-十四氢-1H-萘并[2,1-f]喹啉-2-酮 (3S,13R)-1,2,3,4,4aalpha,5,11,11aalpha-八氢-2,2,5-三甲基-3beta,5beta-乙桥-10bH-吡啶并[3,2-b]咔唑-10bbeta,13-二醇 (3R,6S,6aS,7R,7aS,10S,12aS,13R,13aR,14S,15R)-1-乙基十四氢-12a,14-二羟基-6-甲氧基-3-甲基-8H-13,3,6a-亚乙基-7,10-甲桥氧杂卓并[3,4-i]-1-苯并氮杂环辛四烯-8-酮 (2S,4aR,8aR)-2-甲基八氢-4(1H)-喹啉酮 (2R,4R,4As,8As)-rel-4-乙炔基十氢-1,2-二甲基-4-喹啉醇 (4aS,5R,8aR)-1-(tert-butoxy)carbonyl-2-oxo-5-(triisopropylsilyloxymethyl)decahydroquinoline trans-(+/-)-1-n-propyl-7-oxodecahydroquinoline 3,4,5,6,6a,7,8,9,10,10a-decahydro-(4aβH)-benzo[c]quinolizin-3-one 3,4,5,6,6a,7,8,9,10,10a-decahydro-(4aαH)-benzo[c]quinolizin-3-one 3,4,4a,5,6,7,8-heptahydro-8a-hydrodioxy-2(1H)-quinolinone [2-(2,3-dichloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone (octahydro-quinolin-1-yl)-(2-pyridin-3-yl-thiazol-4-yl)-methanone 2-methylperhydrothiazolo<2,3-j>quinoline 2,4-dichloro-N-[5-((4aRS,8aSR)-octahydroquinoline-1-carbonyl)pyridin-2-yl]benzamide (4aR*,5S*,8aR*)-1,2,3,4,4a,5,6,7,8,8a-Decahydro-5-<(dimethylphenylsilyl)methyl>-1-methylquinoline (4aS*,5S*,8aR*)-1,2,3,4,4a,5,6,7,8,8a-Decahydro-5-<(dimethylphenylsilyl)methyl>-1-(methoxycarbonyl)quinoline (2S,3R,4aS,5R,8aR)-1-(tert-butoxy)carbonyl-3-hydroxy-2-methyl-5-(triisopropylsilyloxymethyl)decahydroquinoline (+/-)-(2SR,4aRS,8aRS)-1-tert-butyloxycarbonyl-5-methylene-2-propyldecahydroquinoline (+/-)-(2SR,4aRS,8aRS)-1-tert-butyloxycarbonyl-2-propyldecahydroquinolin-5-one cis-4-[4-(octahydro-quinoline-1(2H)-ylcarbonyl)-thiophen-2-yl]-piperidine-1-carboxylic acid amide lepadin E (+)-lepadin D cis-(octahydro-quinolin-1(2H)-yl)-(5-piperidin-4-yl-thiophen-3-yl)-methanone 4-methyl-6-(3-methyl-2-thienyl)-4,5,6,7-tetrahydroquinolin-5-one 2,2,4,8-tetramethyldecahydroquinoline 10-oxo-2,5;5,9-diseco-A-dinor-strychnidine-2,5-dioic acid strychnidine-2,3,10-trione 3-tetrazolo-17a-aza-D-homo-3,5-androstadien-17-one 17a-methyl-3-tetrazolo-17a-aza-D-homo-3,5-androstadien-17-one methyl 4-oxooctahydroquinoline-1(2H)-carboxylate decahydro-2-oxo-8-quinolinepropanoic acid ethyl ester 1-octahydro[1]quinolyl-propan-2-ol